Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM - nejm.org


11/11/2023

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM  nejm.orgTrial confirms heart benefits of Wegovy, but is weight loss responsible – or something else?  CNNSemaglutide 'A New Pathway' to CVD Risk Reduction: SELECT  MedscapeNovo Nordisk's weight loss drug Wegovy slashes risk of serious heart events  CNBCFull SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics  TCTMDView Full Coverage on Google News...

Original

Categories: Google | Health | Obesity | Tech

Tags: confirms | coverage | drug | full | google | heart | loss | news | reduction | results | risk | wegovy



Let us know what you think!

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Leave a Comment

Scroll back to top